Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells

Vaccine

Volumn 29, Issue 15, 2011, Pages 2705-2711

  Saccoccio, Frances M ^a   Sauer, Anne L ^a   Cui, Xiaohong ^a   Armstrong, Amy E ^a   Habib, EL Sayed E ^b   Johnson, David C ^c   Ryckman, Brent J ^d   Klingelhutz, Aloysius J ^e   Adler, Stuart P ^a   McVoy, Michael A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MANSOURA UNIVERSITY   (Egypt)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF MONTANA   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

Cytomegalovirus; Mucosal infection; Neutralizing antibody; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; PROTEIN UL128; PROTEIN UL129; PROTEIN UL130; PROTEIN UL131; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CYTOMEGALOVIRUS; EPITHELIUM CELL; MOUTH MUCOSA; NONHUMAN; PRIORITY JOURNAL; RABBIT; VIRUS ENTRY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; CYTOMEGALOVIRUS; EPITHELIAL CELLS; HUMANS; RABBITS; VIRAL PROTEINS; VIRUS INTERNALIZATION;

EID: 79952244625     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.079     Document Type: Article

References (27)

1. Snydman D.R. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transpl Infect Dis 2001, 3(Suppl. 2):6-13.
2. Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005, 353(13):1350-1362.
3. Plotkin S.A., Starr S.E., Friedman H.M., Gonczol E., Weibel R.E. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 1989, 159(5):860-865.
4. Plotkin S.A., Higgins R., Kurtz J.B., Morris P.J., Campbell D.A., Shope T.C., Spector S.A., Dankner W.M. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994, 58(December (11)):1176-1178.
5. Wang D., Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 2005, 102(December (50)):18153-18158.
6. Adler B., Scrivano L., Ruzcics Z., Rupp B., Sinzger C., Koszinowski U. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol 2006, 87(September (Pt 9)):2451-2460.
7. Gerna G., Sarasini A., Patrone M., Percivalle E., Fiorina L., Campanini G., et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 2008, 89(April (Pt 4)):853-865.
8. Macagno A., Bernasconi N.L., Vanzetta F., Dander E., Sarasini A., Revello M.G., et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 2010, 84(January (2)):1005-1013.
9. Hahn G., Revello M.G., Patrone M., Percivalle E., Campanini G., Sarasini A., et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004, 78(September (18)):10023-10033.
10. Ryckman B.J., Jarvis M.A., Drummond D.D., Nelson J.A., Johnson D.C. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol 2006, 80(January (2)):710-722.
11. Dargan D.J., Douglas E., Cunningham C., Jamieson F., Stanton R.J., Baluchova K., et al. Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J Gen Virol 2010, 91(June (Pt 6)):1535-1546.
12. Cui X., Meza B.P., Adler S.P., McVoy M.A. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008, 26(August):5760-5766.
13. Sauer A., Wang J.B., Hahn G., McVoy M.A. A human cytomegalovirus deleted of internal repeats replicates with near wild type efficiency but fails to undergo genome isomerization. Virology 2010, 401(May (1)):90-95.
14. Hobom U., Brune W., Messerle M., Hahn G., Koszinowski U.H. Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol 2000, 74(17):7720-7729.
15. Hahn G., Jarosch M., Wang J.B., Berbes C., McVoy M.A. Tn7-mediated introduction of DNA sequences into bacmid-cloned cytomegalovirus genomes for rapid recombinant virus construction. J Virol Methods 2003, 107(February (2)):185-194.
16. Yu D., Smith G.A., Enquist L.W., Shenk T. Construction of a self-excisable bacterial artificial chromosome containing the human cytomegalovirus genome and mutagenesis of the diploid TRL/IRL13 gene. J Virol 2002, 76(5):2316-2328.
17. Wang D., Bresnahan W., Shenk T. Human cytomegalovirus encodes a highly specific RANTES decoy receptor. Proc Natl Acad Sci USA 2004, 101(November (47)):16642-16647.
18. Wang D., Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005, 79(August (16)):10330-10338.
19. Cui X., McGregor A., Schleiss M.R., McVoy M.A. Cloning the complete guinea pig cytomegalovirus genome as an infectious bacterial artificial chromosome with excisable origin of replication. J Virol Methods 2008, 149(May (2)):231-239.
20. Zabner J., Karp P., Seiler M., Phillips S.L., Mitchell C.J., Saavedra M., et al. Development of cystic fibrosis and noncystic fibrosis airway cell lines. Am J Physiol Lung Cell Mol Physiol 2003, 284(May (5)):L844-L854.
21. Ryckman B.J., Rainish B.L., Chase M.C., Borton J.A., Nelson J.A., Jarvis M.A., et al. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 2008, 82(January (1)):60-70.
22. Ryckman B.J., Chase M.C., Johnson D.C. Human cytomegalovirus TR strain glycoprotein O acts as a chaperone promoting gH/gL incorporation into virions but is not present in virions. J Virol 2010, 84(March (5)):2597-2609.
23. Baldanti F., Paolucci S., Campanini G., Sarasini A., Percivalle E., Revello M.G., et al. Human cytomegalovirus UL131A, UL130 and UL128 genes are highly conserved among field isolates. Arch Virol 2006, 151(June (6)):1225-1233.
24. Patrone M., Secchi M., Fiorina L., Ierardi M., Milanesi G., Gallina A. Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J Virol 2005, 79(July (13)):8361-8373.
25. Adler S.P., Chandrika T., Lawrence L., Baggett J. Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr Infect Dis 1983, 2(March-April (2)):114-118.
26. Yeager A.S., Grumet F.C., Hafleigh E.B., Arvin A.M., Bradley J.S., Prober C.G. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 1981, 98(February (2)):281-287.
27. Adler S.P., Starr S.E., Plotkin S.A., Hempfling S.H., Buis J., Manning M.L., et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995, 171(1):26-32. [published erratum appears in J Infect Dis 1995 Apr;171(4):1080].